FindTrial
Sign In

Anti-PD-1

DRUG5 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Colorado, Denver, Xiangya Hospital of Central South University, TriSalus Life Sciences, Inc., Corbus Pharmaceuticals Inc.

Conditions

Colorectal CancerGlioblastomaGliosarcomaLocally Advanced Pancreatic AdenocarcinomaMelanoma (Skin)Microsatellite Instability HighMismatch Repair DeficiencyRecurrent Brain Neoplasm

Phase 1

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
CompletedNCT02658981
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsGlioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
Start: 2016-08-24End: 2023-10-03Updated: 2023-10-06
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
NCT04072900
Xiangya Hospital of Central South UniversityMelanoma (Skin)
Start: 2020-04-21End: 2022-09-01Target: 30Updated: 2020-04-28
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
Active, not recruitingNCT05607953
TriSalus Life Sciences, Inc.Locally Advanced Pancreatic Adenocarcinoma
Start: 2023-03-01End: 2027-10-31Target: 60Updated: 2025-07-04
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
RecruitingNCT06265727
Corbus Pharmaceuticals Inc.Solid Tumor, Adult
Start: 2024-04-01End: 2027-01-27Target: 348Updated: 2026-01-08

Phase 2

Anti-PD-1 +/- RT for MSI-H Solid Tumors
WithdrawnNCT04001101
University of Colorado, DenverColorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency
Start: 2019-10-10End: 2021-11-17Updated: 2021-11-30

Related Papers

Phase I dose-escalation study of the next-generation nectin-4 targeting antibody–drug conjugate CRB-701 (SYS6002) in US and UK patients with urothelial cancer and other solid tumors.
Journal of Clinical Oncology2025-02-101 citations
647 PERIO-03: Pressure enabled intrapancreatic delivery of SD-101 with checkpoint blockade for locally advanced pancreatic adenocarcinoma – Initial safety and feasibility experience
Regular and Young Investigator Award Abstracts2023-10-313 citations
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM.
Journal of Clinical Oncology2020-05-2019 citations
IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM
Neuro-Oncology2019-11-011 citations
Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM.
Journal of Clinical Oncology2019-05-2020 citations